While you might think a cancer diagnosis is a single, grim statistic, survival rates tell a more nuanced and often hopeful story, with figures ranging from nearly 100% for early-stage breast and prostate cancers to the sobering challenges of pancreatic and lung cancers.
Key Takeaways
- The 5-year relative survival rate for localized female breast cancer in the United States (diagnosed 2014-2020) is 99.3%
- The 5-year relative survival rate for regional female breast cancer in the United States (diagnosed 2014-2020) is 86.4%
- The 5-year relative survival rate for distant female breast cancer in the United States (diagnosed 2014-2020) is 30.8%
- The 5-year relative survival rate for localized non-small cell lung cancer (NSCLC) in the US (2014-2020) is 63%
- 5-year survival for regional NSCLC in US (2014-2020) is 34%
- Distant NSCLC 5-year survival in US is 8% (2014-2020)
- The 5-year relative survival for localized colorectal cancer in the US (2014-2020) is 91%
- Regional colorectal cancer 5-year survival in US is 72% (2014-2020)
- Distant colorectal cancer 5-year survival is 15% (US 2014-2020)
- The 5-year relative survival for localized prostate cancer in the US (2014-2020) is 100%
- Regional prostate cancer 5-year survival in US is 100% (2014-2020)
- Distant prostate cancer 5-year survival is 34% (US 2014-2020)
- The 5-year relative survival for pancreatic cancer localized in US (2014-2020) is 44.3%
- Regional pancreatic cancer 5-year survival US 16.3% (2014-2020)
- Distant pancreatic 5-year survival 3.4% (US)
Cancer survival rates improve dramatically when caught early and localized.
Breast Cancer
1The 5-year relative survival rate for localized female breast cancer in the United States (diagnosed 2014-2020) is 99.3%
Verified2The 5-year relative survival rate for regional female breast cancer in the United States (diagnosed 2014-2020) is 86.4%
Verified3The 5-year relative survival rate for distant female breast cancer in the United States (diagnosed 2014-2020) is 30.8%
Verified4The 5-year relative survival rate for all stages of female breast cancer in women under 50 in the UK (2016-2020) is 92%
Directional5Age-standardized 5-year net survival for breast cancer in women aged 15-99 in Australia (2014-2018) is 90.8%
Single source6The 10-year relative survival rate for localized breast cancer in Japanese women (2006-2008) is 98.5%
Verified75-year survival rate for HER2-positive breast cancer treated with trastuzumab in Europe (2005-2012) is 87%
Verified8The 5-year overall survival for triple-negative breast cancer in the US (stage I-II) is 91%
Verified9In Canada, the 5-year net survival for breast cancer diagnosed 2015-2017 is 88.6% for females
Directional105-year relative survival for breast cancer in Black women in the US (2014-2020) is 82.7%
Single source11For women over 75 with early-stage breast cancer in the US, 5-year survival is 92.1% (2014-2020)
Verified12In Germany, 5-year relative survival for breast cancer (2015-2020) is 90.2%
Verified13The 5-year survival rate for DCIS breast cancer in the US is nearly 100%
Verified14In India, 5-year survival for breast cancer stage III is 52% (urban centers, 2010-2015)
Directional15Sweden's 10-year breast cancer survival rate (2010-2015) is 84%
Single source16For BRCA1 mutation carriers with breast cancer, 5-year survival is 88.5% (US cohort 2000-2015)
Verified17In France, 5-year standardized survival for breast cancer is 91% (2018 data)
Verified185-year survival for inflammatory breast cancer in the US is 41% (all stages)
Verified19Brazil's 5-year survival for localized breast cancer is 92.1% (2000-2015)
Directional20In the Netherlands, 5-year relative survival for breast cancer improved to 92% by 2015-2019
Single source21For Asian/Pacific Islander women in US, breast cancer 5-year survival is 95.1% (2014-2020)
Verified22Italy's 5-year net survival for breast cancer (2013-2015) is 88%
Verified235-year survival for male breast cancer in US is 88.1% (localized)
Verified24In South Korea, breast cancer 5-year survival rose to 93.4% (2014-2018)
Directional25US Hispanic women breast cancer 5-year survival is 90.2% (2014-2020)
Single source265-year survival for Paget disease of the breast is 85-90% if underlying DCIS (US data)
Verified27In China, urban breast cancer 5-year survival is 82.1% (2003-2005 cohort)
Verified28Norway's 5-year breast cancer survival is 92.8% (2017-2021)
Verified29For postmenopausal women on hormone therapy, breast cancer survival is 89% at 5 years (UK study)
Directional305-year relative survival for breast cancer in US white women is 92.0% (2014-2020)
Single sourceBreast Cancer Interpretation
These numbers tell a clear and crucial story: catching breast cancer early is a near-guarantee of survival, while letting it spread turns the odds into a terrifying coin toss.
Colorectal Cancer
1The 5-year relative survival for localized colorectal cancer in the US (2014-2020) is 91%
Verified2Regional colorectal cancer 5-year survival in US is 72% (2014-2020)
Verified3Distant colorectal cancer 5-year survival is 15% (US 2014-2020)
Verified4Overall 5-year survival for colorectal cancer in UK (2016-2020) is 60%
Directional5Australia's 5-year survival for colorectal cancer (2014-2018) is 69.8%
Single source6In Canada, colorectal cancer 5-year net survival (2015-2017) is 65.1%
Verified75-year survival for rectal cancer localized in US is 89% (2014-2020)
Verified8Germany's 5-year relative survival for colorectal cancer is 65% (2015-2020)
Verified9Japan colorectal cancer 5-year survival is 66.5% (2010-2014)
Directional10Sweden colorectal 5-year survival 70% (2010-2015)
Single source11Stage II colon cancer 5-year DFS 80-85% with adjuvant chemo (US trials)
Verified12France colorectal cancer 5-year survival 67% (2018)
Verified13Italy 5-year net survival colorectal cancer 66% (2013-2015)
Verified14South Korea colorectal 5-year survival 72.8% (2014-2018)
Directional15China colorectal 5-year survival 56.9% urban (2003-2005)
Single source16Norway colorectal 5-year survival 71% (2017-2021)
Verified17US Black patients colorectal 5-year survival 59% (2014-2020)
Verified18Netherlands colorectal 5-year survival 65% (2015-2019)
Verified19For MSI-high colorectal cancer, 5-year survival 75% stage II-III (US)
Directional20Brazil colorectal 5-year survival 62.6% (2000-2015)
Single source21India stage III colorectal 5-year survival 45% (2010-2015 urban)
Verified225-year survival post-liver metastectomy from colorectal ca is 50-60% (Europe)
Verified23Elderly (>80) localized colorectal 5-year survival 75% (US SEER)
Verified24Women colorectal cancer 5-year survival 64% vs men 60% (US)
Directional25Right-sided colon cancer 5-year survival 62% vs left 70% (US data)
Single sourceColorectal Cancer Interpretation
These numbers tell a sobering but clear story: catching colorectal cancer early is your best shot, as the survival rate plummets from a hopeful 91% when it's local to a grim 15% once it spreads, highlighting a crucial gap between what's possible and the uneven reality across nations and demographics.
Lung Cancer
1The 5-year relative survival rate for localized non-small cell lung cancer (NSCLC) in the US (2014-2020) is 63%
Verified25-year survival for regional NSCLC in US (2014-2020) is 34%
Verified3Distant NSCLC 5-year survival in US is 8% (2014-2020)
Verified4Overall 5-year survival for lung cancer in UK (2016-2020) is 18%
Directional5In Australia, 5-year survival for lung cancer (2014-2018) is 19.6%
Single source65-year survival for small cell lung cancer (SCLC) limited stage in US is 29% (2014-2020)
Verified7Extensive stage SCLC 5-year survival in US is 3% (2014-2020)
Verified8In Canada, lung cancer 5-year net survival (2015-2017) is 19.3%
Verified95-year survival for lung cancer in never-smokers in US is 25% (SEER data)
Directional10Germany's 5-year relative survival for lung cancer (2015-2020) is 20.1%
Single source11In Japan, 5-year survival for lung cancer improved to 33% (2010-2014)
Verified12Sweden's 5-year lung cancer survival is 22% (2010-2015)
Verified13For stage I NSCLC treated with SBRT, 5-year survival is 80-90% (US meta-analysis)
Verified14In France, lung cancer 5-year survival is 17% (2018)
Directional15Italy's 5-year net survival for lung cancer (2013-2015) is 16%
Single source16South Korea lung cancer 5-year survival is 30.4% (2014-2018)
Verified17In China, lung cancer 5-year survival is 19.7% (urban, 2003-2005)
Verified18Norway's lung cancer 5-year survival is 24.5% (2017-2021)
Verified19For EGFR-mutant NSCLC with TKIs, 5-year OS is 35% (global trial)
Directional20US Black patients lung cancer 5-year survival is 16% (2014-2020)
Single source21In the Netherlands, lung cancer 5-year survival is 21% (2015-2019)
Verified22Adenocarcinoma lung cancer 5-year survival 25% vs squamous 15% (US)
Verified23Brazil lung cancer 5-year survival is 15.2% (2000-2015)
Verified24For elderly (>75) with early lung cancer, 5-year survival 55% post-surgery (US)
Directional25India lung cancer 5-year survival stage IV is 5% (urban 2010-2015)
Single source265-year survival for resected stage IIIA NSCLC is 36% (US data)
Verified27In women, lung cancer 5-year survival is 25% vs 18% in men (US 2014-2020)
VerifiedLung Cancer Interpretation
The stark drop in survival rates from localized to distant lung cancer paints a grim but crucial map, reminding us that early detection isn't just a cliché—it's the chasm between a 63% chance and an 8% chance.
Other Cancers
1The 5-year relative survival for pancreatic cancer localized in US (2014-2020) is 44.3%
Verified2Regional pancreatic cancer 5-year survival US 16.3% (2014-2020)
Verified3Distant pancreatic 5-year survival 3.4% (US)
Verified4Overall liver cancer 5-year survival UK 20% (2016-2020)
Directional5Leukemia all types 5-year survival US 65.7% (2017-2021)
Single source6Acute myeloid leukemia 5-year survival 31.9% (US adults)
Verified7Non-Hodgkin lymphoma 5-year survival 74% US (2017-2021)
Verified8Ovarian cancer localized 5-year survival 93.2% US (2014-2020)
Verified9Bladder cancer localized 5-year 70% US
Directional10Kidney cancer 5-year survival 76.4% US overall (2014-2020)
Single source11Brain cancer 5-year survival 36.4% US (2017-2021)
Verified12Thyroid cancer 5-year survival 98.4% US (2014-2020)
Verified13Melanoma localized 5-year 99.6% US
Verified14Esophageal cancer 5-year survival 21.7% US overall
Directional15Stomach cancer localized 75.3% 5-year US
Single source16Uterine corpus 5-year survival 81.8% US
Verified17Multiple myeloma 5-year survival 59.8% US (2017-2021)
Verified18Soft tissue sarcoma 5-year 65.3% US localized
Verified19Testicular cancer 5-year 95.3% US overall
Directional20Oral cavity cancer 5-year localized 84.6% US
Single source21Cervical cancer localized 91.2% 5-year US
Verified22Hodgkin lymphoma 5-year 89.1% US
Verified23Mesothelioma 5-year survival 12.4% US
VerifiedOther Cancers Interpretation
This data paints a stark and geographically inconsistent map of human vulnerability, reminding us that the battleground of cancer is not just in the body, but in the organ itself, where a tumor in the thyroid is nearly a guarantee while one in the pancreas remains a profound threat.
Prostate Cancer
1The 5-year relative survival for localized prostate cancer in the US (2014-2020) is 100%
Verified2Regional prostate cancer 5-year survival in US is 100% (2014-2020)
Verified3Distant prostate cancer 5-year survival is 34% (US 2014-2020)
Verified4Overall 5-year survival for prostate cancer in UK (2016-2020) is 88%
Directional5Australia prostate cancer 5-year survival (2014-2018) is 95.1%
Single source6Canada prostate 5-year net survival (2015-2017) is 94.3%
Verified7Germany's 5-year relative survival prostate cancer 92% (2015-2020)
Verified8Japan prostate 5-year survival 97.6% (2010-2014)
Verified9Sweden prostate 5-year survival 95% (2010-2015)
Directional10Low-risk prostate cancer active surveillance 10-year metastasis-free survival 98% (US)
Single source11France prostate 5-year survival 94% (2018)
Verified12Italy prostate 5-year net survival 91% (2013-2015)
Verified13South Korea prostate 5-year survival 97.4% (2014-2018)
Verified14China prostate 5-year survival 58.1% (2003-2005 urban)
Directional15Norway prostate 5-year survival 96% (2017-2021)
Single source16US Black men prostate 5-year survival 96.5% (2014-2020)
Verified17Netherlands prostate 5-year survival 94% (2015-2019)
Verified18Gleason 6 prostate cancer 15-year prostate cancer-specific survival 97% (US)
Verified19Brazil prostate 5-year survival 88.4% (2000-2015)
Directional20High-risk prostate cancer 5-year biochemical recurrence-free survival 70% post-RP (Europe)
Single source21Metastatic castration-resistant prostate cancer median OS 30 months with novel agents (global)
Verified22Men over 75 localized prostate 5-year survival 100% (US SEER)
Verified23PSMA PET-guided salvage RT improves 3-year freedom from progression to 74% (US trial)
Verified2410-year CSS for intermediate-risk prostate cancer is 95% (US cohorts)
Directional25India prostate cancer 5-year survival stage III 60% (urban 2010-2015)
Single sourceProstate Cancer Interpretation
It's sobering to realize that while prostate cancer is overwhelmingly survivable when caught early, geography and access to care still write the final chapter for far too many men.
Sources & References
- Reference 1SEERseer.cancer.govVisit source
- Reference 2CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 3AIHWaihw.gov.auVisit source
- Reference 4PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 5NCBIncbi.nlm.nih.govVisit source
- Reference 6CANCERcancer.orgVisit source
- Reference 7CANCERcancer.caVisit source
- Reference 8KREBSDATENkrebsdaten.deVisit source
- Reference 9BREASTCANCERbreastcancer.orgVisit source
- Reference 10NCPRncpr.seVisit source
- Reference 11JAMANETWORKjamanetwork.comVisit source
- Reference 12E-CANCERe-cancer.frVisit source
- Reference 13CANCERcancer.govVisit source
- Reference 14IKNLiknl.nlVisit source
- Reference 15AIOMaiom.itVisit source
- Reference 16NCCncc.re.krVisit source
- Reference 17KREFTREGISTERETkreftregisteret.noVisit source
- Reference 18GANJOHOganjoho.jpVisit source
- Reference 19NEJMnejm.orgVisit source
- Reference 20AUANETauanet.orgVisit source